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Abstract
We investigated the effects of the matrix metalloproteinase 13 (MMP13)-selective inhibitor, 5-(4-{4-[4-(4-fluorophenyl)-1,3-
oxazol-2-yl]phenoxy}phenoxy)-5-(2-methoxyethyl) pyrimidine-2,4,6(1H,3H,5H)-trione (Cmpd-1), on the primary tumor
growth and breast cancer-associated bone remodeling using xenograft and syngeneic mouse models. We used human
breast cancer MDA-MB-231 cells inoculated into the mammary fat pad and left ventricle of BALB/c Nu/Nu mice, respectively,
and spontaneously metastasizing 4T1.2-Luc mouse mammary cells inoculated into mammary fat pad of BALB/c mice. In a
prevention setting, treatment with Cmpd-1 markedly delayed the growth of primary tumors in both models, and reduced
the onset and severity of osteolytic lesions in the MDA-MB-231 intracardiac model. Intervention treatment with Cmpd-1 on
established MDA-MB-231 primary tumors also significantly inhibited subsequent growth. In contrast, no effects of Cmpd-1
were observed on soft organ metastatic burden following intracardiac or mammary fat pad inoculations of MDA-MB-231
and 4T1.2-Luc cells respectively. MMP13 immunostaining of clinical primary breast tumors and experimental mice tumors
revealed intra-tumoral and stromal expression in most tumors, and vasculature expression in all. MMP13 was also detected
in osteoblasts in clinical samples of breast-to-bone metastases. The data suggest that MMP13-selective inhibitors, which lack
musculoskeletal side effects, may have therapeutic potential both in primary breast cancer and cancer-induced bone
osteolysis.
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Introduction
The human matrix metalloproteinase (MMP) family comprises
26 zinc-dependent transmembrane and secreted neutral endopep-
tidases that contribute to homeostasis of the extracellular matrix
[1]. MMPs are involved in a variety of physiological and
pathological signaling processes characterized by tissue destruc-
tion, including arthritis, atherosclerosis and cancer. These
proteases have been implicated in multiple facets of tumorigenesis,
including primary tumor growth, angiogenesis, local invasion/
migration, intravasation and extravasation, and also in the
establishment and growth of metastatic lesions [1].
MMPs are synthesized by tumor cells, but predominantly
produced by the surrounding stromal cells [2]. Important anti-
tumoral roles for several MMPs have been revealed, and these
may partly explain the failure of early MMP inhibitor trials [3]. In
addition, early clinical trials were hampered by a lack of efficacy
markers to guide dosing, and by dose-limiting toxicity such as
musculoskeletal syndrome (MSS), which is characterized by
painful stiffening of joints, tendonitis, soft tissue fibroplasias and
inflammation [3]. The development of agents that specifically
inhibit individual MMPs associated with particular cancers is
postulated to provide effective therapeutics that may overcome
these problems [4].
MMP13 may be such a candidate. Its selective inhibition may
be clinically beneficial over the relatively non-selective broad-
spectrum MMP inhibitors based on the fact that MMP13
expression is largely restricted to pathological conditions including
various carcinomas. For example, elevated levels of MMP13 have
been associated with decreased overall survival and lymph node
metastasis in breast cancer [5], bone metastasis in renal cell
carcinoma [6], poor prognosis of non-small cell lung and
colorectal cancers [7,8] and invasive capability in various other
human cancers including melanoma, head and neck and vulvar
squamous cell carcinoma [9]. Furthermore, stroma-derived
MMP13 was recently found to be involved in the growth and
organ-specific metastasis of melanoma [10]. We have previously
shown that MMP13 was dramatically induced in the tumor-
associated stroma of human breast cancer xenografts [11].
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in bone cancer and cancers that frequently metastasize to bone,
such as breast and prostate cancer and multiple myeloma
[14,15,16]. In particular, a recent finding demonstrates MMP13
as a key regulator in osteolytic bone metastasis [17], where its
expression may be induced in osteoblats by tumor-cell derived
factors such as oncostatin M and the acute response apolipopro-
tein SAA3 [18]. It is uniquely expressed by osteoblasts and
hypertropic chondrocytes during foetal bone development, but
otherwise its expression is minimal under physiological conditions
in adult tissues. It is expressed during collagenous tissue repair or
remodeling [9,19], and during fibrogenesis and wound healing,
where it has been found to accelerate repair [20,21]. MMP13 has
been implicated in the cartilage damage of human osteoarthritis
and rheumatoid arthritis [22,23] and lack of MMP13 was shown
to halt cartilage erosion in established osteoarthritis [24].
MMP13 lends itself to specific inhibition due to a relatively deep
S19 pocket [25]. Computational modeling has led to the
identification of a panel of pyrimidinetrione-based inhibitors that
are selective for MMP13 due to their binding in its deep S19
pocket [26,27]. The inhibitor used in this study, 5-(4-{4-[4-(4-
fluorophenyl)-1,3-oxazol-2-yl]phenoxy}phenoxy)-5-(2-methoxyethyl)-
pyrimidine-2,4,6 (1H,3H, 5H)-trione (Cmpd-1 which is Cmpd-28 in
ref. 26), was chosen from a panel of small molecule MMP13-selective
inhibitors for its potency and lack of deleterious side effects of a closely
related compound in an animal model of MSS [27]. Here we
investigate the inhibitory effects of Cmpd-1 on the growth of primary
tumors, the incidence and development of tumor-associated osteolytic
lesions in the MDA-MB-231 human xenograft and 4T1.2 murine
syngeneic models of breast cancer. Our results demonstrate reduced
primary tumor growth in both models and delayed development of
osteolytic bone lesions in the xenograft model.
Materials and Methods
Breast cancer cells
We used human MDA-MB-231 cells transfected with the
bacterial b-galactosidase (MDA-MB-231-BAG1 cells) and 4T1.2
mouse mammary cells [28,29,30] engineered to express luciferase
(kindly provided by A/Prof. Robin Anderson, Peter MacCallum
Cancer Centre, Melbourne, Australia; Luciferase expression in
4T1.2 cells by Dr. John Price, Monash Medical Centre,
Melbourne, Australia). MDA-MB-231-BAG1 (hereafter referred
to as MDA-MB-231) and 4T1.2-Luc (referred to as 4T1.2) cells
were routinely cultured in RPMI-1640 and DMEM complete
growth medium, respectively (Gibco BRL, Australia) supplement-
ed with 10% fetal bovine serum (Gibco BRL, Victoria, Australia)
in a 37uC/5% CO2 humidified incubator.
Induction of primary tumor growth and bone osteolysis
by inoculation of breast cancer cells into mice
For the prevention study in the xenograft model, intra-cardiac
inoculation of MDA-MB-231 cells into 4 week old female BALB/c
Nu/Nu mice (Animal Resources Centre, Perth, Australia) was
performed as previously described [31,32]. Briefly, each mouse
was inoculated under anesthesia in the left ventricle with 2610
5
MDA-MB-231 cells in 100 ml PBS. Another group of 4 week old
female mice were inoculated with MDA-MB-231 cells bilaterally
into the mammary fat pad (5610
5 cells in 15 ml PBS into each), as
previously described [31]. 4T1.2 cells were inoculated bilaterally
into the mammary fat pad (5610
5 cells in 15 ml PBS into each site)
of 5–7 weeks old female wild-type BALB/c mice (Animal
Resources Centre) for the prevention study as described above.
For the intervention study, BALB/c Nu/Nu female mice were
inoculated with MDA-MB-231 breast cancer cells in the
mammary fat pad, as described above, with treatments started
later as detailed below. The mouse studies were conducted with
approval of the St Vincent’s Hospital Animal Ethics Committee
(AEC#35/08) and in accordance with the Australian National
Health and Medical Research Council’s guidelines for the care
and use of laboratory animals.
Administration of Cmpd-1
Cmpd-1 powder was synthesized at Pfizer (Groton, CT, USA)
and prepared freshly in vehicle solution (20 mM citric acid,
3.5 mM sodium citrate, 50% v/v polyethylene glycol 400, 10%
w/v hypromellose (Sigma-Aldrich). A schematic presentation of
the timeline for Cmpd-1 treatment used in the various mouse
studies is shown in Figure 1. For the prevention studies, the mice
were dosed from 2 days after the inoculation of the cells by oral
gavage with vehicle (n=10) or Cmpd-1 at low dose (25 mg/kg of
mice body weight; n=10) or high dose (50 mg/kg; n=10), twice
daily at ,12 h intervals. These doses were chosen to provide
selective inhibition of MMP13 over other MMPs (see discussion)
and had been well tolerated by rats in previous Pfizer studies (data
not shown). However, due to some adverse observations, the high
dose regimen was reduced to low dose on Days 10 and 17 for the
MDA-MB-231 mammary fat pad and intra-cardiac experiments,
respectively. The high dose regimen was therefore renamed as the
two-tier regimen for the MDA-MB-231 experiments. These
adverse responses were not seen in later experiments. An
additional group of intra-cardiac inoculated mice (n=10)
commenced weekly dosing with the bisphosphonate zolendronic
acid (Zometa; supplied by Novartis, Basel, Switzerland - sc
injections of 100 mg/kg) for three weeks based on previous studies
[33], with the first dose provided 3 days after cancer cell
inoculation. The 4T1.2-inoculated BALB/c mice were dosed with
either vehicle (n=8) or Cmpd-1 at low dose (25 mg/kg of mice
body weight; n=8) or high dose (50 mg/kg; n=8) by oral gavage
twice daily at ,12 h intervals, starting on Day 2. The high dose of
Cmpd-1 was continued throughout the experiment duration until
the harvest. An intervention study was performed with the MDA-
MB-231 xenografts to examine the effect of Cmpd-1 on
established tumors and mimic the treatment in human breast
cancer patients. The mice were monitored for tumor growth after
mammary fat pad inoculations of MDA-MB-231 cells and
randomised for the Cmpd-1 treatment when the average tumor
sizes were ,120 mm
3. The mice were dosed from Day 27 with
either vehicle (n=7) or high dose Cmpd-1 (50 mg/kg of mice
body weight; n=8) by oral gavage twice daily at ,12 h intervals,
until the end of the experiment on Day 43.
X-ray analysis, tumor measurements, bioluminescent
imaging and harvesting of tumors, blood and soft organs
For the mammary fat pad xenograft model, tumor-bearing mice
were monitored thrice weekly for body weight and tumor size.
Once palpable, the tumor sizes were measured thrice weekly in
two dimensions using digital calipers, and culled when tumor size
approached 10% of body weight. To assess osteolytic damage of
intra-cardially inoculated MDA-MB-231 mice, the hind limbs
were subjected to high resolution X-ray analysis (Faxitron, USA;
20 mm focal source) thrice a week from week 2, as previously
described [32]. These mice demonstrated extensive bone destruc-
tion and were harvested as soon as they showed any adverse signs
or symptoms of disease or morbidity; otherwise at an experimental
endpoint of 55 days post inoculation. Blood collected immediately
prior to organ harvest was obtained by cardiac puncture from a
limited number of mice and allowed to clot overnight at 4uC, after
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stored at 280uC until analysis. Lungs and brain were snap-frozen
and the level of metastatic burden quantitated by Alu PCR, as
described below.
The mice bearing 4T1.2 cells, in addition to the routine
monitoring as described above, were subjected to luminescence
detection using the IVIS system (Xenogen). Mice were anesthe-
tized as described previously [31,32], and luciferase signal was
measured by intraperitoneal delivery of luciferin (112 mg/kg in
PBS; 15 mg/ml) 10 mins before imaging and analysing photon
emissions from the tumor cells at fixed time points over the length
of the experiment. Ex-vivo lung imaging was performed
immediately following the euthanising of mice, to detect the
amount of lung metastasis. These mice were harvested after 3
weeks of cell inoculations unless harvested early due to signs of
distress. Luminescence intensity was used to quantify the
metastasis in lung.
Quantification of metastatic burden in soft tissue organs
AluPCRanalysis was performedto quantitatemetastaticburden
in lungs and brain collected from mice inoculated intracardially
with MDA-MB-231 cells, as previously described [34], on 10 ng of
purified genomic DNAin a Rotor-Gene 6000 series system (Corbett
Research, Sydney, Australia). On each 72-well reaction disk, a
standard curve was prepared by serially diluting human DNA into
mouse DNA, permitting the quantification of the tissue burden of
human tumor cells in the mouse organs removed at autopsy.
Metastatic burden is indicated by the proportion of human DNA
found in each organ, expressed as a percentage.
In the 4T1.2 model, representative lungs (n=4 per group) were
fixed in formalin, embedded in paraffin and subjected to serial
sections of 10 mm thickness. The process was repeated through the
entire lung and every tenth section was stained with Haematoxylin
and Eosin following routine procedures.
Analysis of serum concentrations of Cmpd-1 and creatine
kinase
Cmpd-1 concentrations in serum were quantified using a high
performance liquid chromatography–tandem mass spectrometry
(HPLC/MS/MS) assay. Serum samples were thawed on ice and
150 ml of acetonitrile containing 5-(4-{[1-(4-fluorophenyl)-1H-
indazol-5-yl]oxy}phenoxy)-5-(2-methoxyethyl)pyrimidine-2,4,6(1H,
3H,5H)-trione (an analogue of Cmpd-1) was added as an internal
standard to 50 ml of undiluted sample, diluted sample (1 part serum
and 9 parts control serum), and standard. The samples were then
vortexed and centrifuged at 500 g for 10 minutes. The supernatants
(150 ml) were transferred to a 96-well plate for analysis by HPLC/
MS/MS, using transition state monitoring of 532.2/347.2 and
505.5/320.2 for Cmpd-1 and its analogue, respectively, in the
positive ion mode. The dynamic range of the assay was 0.010 to
10 mg/ml.
As a general measure of musculoskeletal toxicity, which has
been reported for MMP inhibitors, we assessed serum levels of
creatine kinase collected from the 4T1.2 experiment following the
manufacturer’s protocol (CK-NAC, Beckman Coulter Inc. CA,
USA).
Statistical analyses
Data were analysed using Graph Pad Prism 5.0 (GraphPad
Software Inc). Two-way repeated measures (RM) ANOVA was
performed to compare the mammary fat pad tumor sizes between
control and treatment groups. The Bonferroni post-test was
performed to determine at which time points tumor sizes varied
between treatment regimens. Tumor did not grow in one of the
Figure 1. Cmpd-1 treatment timeline of prevention and intervention studies in xenograft and syngeneic mouse models.
doi:10.1371/journal.pone.0029615.g001
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MDA-MB-231, and this sample was excluded from the analysis, as
was the data from two mice in the low Cmpd-1 group that died
early in the experiment due to unrelated health issues. Time to
reach specified lesion scores for osteolytic damage between control
and treatment groups and percent survival after cancer cell
inoculation were analysed using the Kaplan-Meier method, with P
values calculated using the log-rank test. Metastasis levels to soft
organs determined by Alu PCR were compared using the Mann-
Whitney test. One-way ANOVA was performed to compare
serum levels of CK between the control and treatment groups.
Values are indicated as mean 6 SEM. P values,0.05 were
considered statistically significant in all comparisons.
MMP13 immunofluorescence and localisation in primary
breast tumors and bone metastasis clinical samples, and
in experimental tumors
Human breast tumors were collected with the approval of the St
Vincent’s Hospital Human Research Ethics committee (SVH
HREC-A), Melbourne, Australia. The need for individual patient
consent was waived by the SVH HREC-A as tissues were collected
by the hospital for hospital procedures and individual patients
cannot be identified unduly, and the project would not impact on
tissue donors’ disease or treatment. The clinico-pathological
characteristics and formalin-fixed paraffin-embedded (FFPE)
tumor sections of primary breast invasive ductal carcinomas
(IDCs) from patients (n=8) who underwent surgery and had no
preoperative treatments, were obtained from the archives of the
Dept. of Anatomical Pathology, St. Vincent’s Hospital, Mel-
bourne. Immunofluorescence on tumors from clinical breast
cancer samples, and xenograft and syngeneic mouse models was
performed essentially as described [11], using sheep anti-human
MMP13 serum (kindly provided by Prof. Gillian Murphy,
Cambridge Institute of Medical Research, UK). Fluorescence
microscopy was performed on an AxioCam MRC5 instrument
and images were acquired at 406magnification using Axiovision
v4.8 software (Zeiss, Go ¨ttingen, Germany). Propidium iodide was
used as a nuclear stain.
Human de-identified samples of frank breast to bone metastases
(n=5) were obtained under an Institutional Review Board
approved protocol at Vanderbilt University Medical Center,
Nashville, TN, USA. All human specimens for research were
collected with patients’ written consent. Fluorescent tartrate-
resistant acid phosphatase (TRAcP) staining for osteoclast
detection (Elf97; Invitrogen) and immunofluorescent staining for
MMP13 (1:250 dilution; RP1-MMP13, Triple Point Biologics,
USA) was performed from FFPE sections as previously described
[35,36]. Rabbit IgG (Sigma-Aldrich) was used as a control but
neither staining for the isotype control nor autofluorescence in the
red channel (ex-568 nm) was detected (data not shown). DAPI, at
a final concentration of 1 nm was used as a nuclear stain.
Ki67 staining of MDA-MB-231 Bag1 and 4T1.2-Luc
primary tumors
IHC analysis was performed for Ki67 on 5 mm FFPE sections
from xenograft and syngeneic mice tumors. To retrieve the
antigenicity, the tissue sections were boiled in 10 mmol/L citrate
buffer (pH 6.0) for 20 min. IHC was performed using the
peroxidase method. The primary antibodies used were mouse
anti-human Ki67 (Clone MIB1 #3707: DAKO Australia @
1:100) and rabbit anti-mouse Ki67 (clone SP6 #RM-9106-S0;
Labvision Australia @ 1:500). Non-immunized IgG (DAKO
Australia) at an equivalent concentration to the primary target
antibody was used as a negative control. Endogenous peroxidases
were blocked with 3% H2O2. Slides were incubated with primary
antibodies at 4uC overnight followed by the incubation with
secondary antibody (Dako rabbit anti-mouse and goat anti-rabbit
HRP secondary at 1:1000 dilution) for 1 hour at room
temperature before visualisation with DAB for 8 min. Slides were
counterstained with Mayer’s haematoxylin.
Results
Early treatment of Cmpd-1 impacts upon the growth of
primary tumors and the onset and severity of osteolytic
lesions in the xenograft model: a prevention study
Mouse body weights did not differ between Cmpd-1 treatment
groups over the course of the experiment (data not shown). Early
deaths seen in the low Cmpd-1 regimen MDA-MB-231 mammary
fat pad group appeared unrelated to Cmpd-1 since they were not
seen in the high dose group, as also confirmed in the following
experiments. As demonstrated in Figure 2A, primary MDA-MB-
231 xenograft growth was markedly inhibited by treatment with
either the low Cmpd-1 regimen (p=0.0018) or the two-tier Cmpd-
1 regimen (p,0.0001), the latter being more effective than the
former (p=0.043). Differences in tumor size between vehicle
Figure 2. Prevention studies with Cmpd-1 and its effect on
primary tumor growth in the MDA-MB-231 human breast
cancer xenograft model. (A) Three groups of mice inoculated with
cells at day 0 were treated with vehicle (n=10) or either of the low dose
(25 mg/kg twice daily; n=10) or two-tier (50 mg/kg for initial 10 days
and then reduced to low dose; n=10) Cmpd-1 regimens from day 2
until the end point of the experiment. There was a significant dose-
dependent effect of Cmpd-1 on the inhibition of primary tumor growth
(vehicle vs. low dose p=0.0018; vehicle vs. two-tier p,0.0001; ANOVA
and Bonferroni post-test). Tumor measurements plotted are expressed
as the mean 6 S.E.M. (B) Mice treated with low or two-tier Cmpd-1
regimen showed prolonged survival compared to vehicle control
(p=0.0066 and p,0.0001, respectively; Kaplan-Meier survival).
doi:10.1371/journal.pone.0029615.g002
MMP13 Inhibition - Breast Tumor Growth & Osteolysis
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29615control and treatment groups became significant from 28 days post
inoculation (Figure 2A). Furthermore, Kaplan-Meier survival in
mice treated with low (p=0.0066) or two-tier (p,0.0001) Cmpd-1
was prolonged compared to vehicle control, as determined at the
time of harvest (Figure 2B).
The degree of osteolytic damage in the proximal tibia of mice
following intra-cardiac seeding of MDA-MB-231 cells was scored
using a semi-quantitative scale (where a score of 0 represents no
visible osteolytic damage, 1 represents visible damage that may
disappear in the subsequent analysis, 2 represents definite
damage unlikely to disappear, 3 represents substantial damage
and 4 represents severe/extensive damage) [32]. The times to
reach the onset of definite osteolytic damage (score 2, Figure 3A)
and substantial osteolytic damage (score 3, Figure 3B) were
analyzed. Zometa, a bisphosphonate known to block osteoclast
mediated bone resorption in mouse models of breast-bone
metastasis, completely abrogated the formation of osteolytic bone
lesions while both treatment regimens for Cmpd-1 caused a
significant reduction in lesion onset shown in Figure 3A (score 2,
vehicle vs low Cmpd-1 p=0.027, vehicle vs two-tier Cmpd-1
p=0.0037). A significant reduction in the incidence of substantial
osteolytic damage was also seen in mice treated with two-tier
Cmpd-1 (score 3, vehicle vs two-tier Cmpd-1 p=0.017;
Figure 3B), but not low Cmpd-1. The inhibitory effects of low
and two-tier Cmpd-1 are shown in the representative Faxitron
images of Figure 3C.
Figure 3. Prevention treatment with Cmpd-1 and its effect on osteolytic damage in the tibiae bones. (A) Three groups of mice were
inoculated with MDA-MB-231 cells intracardially at day 0 and were treated with vehicle (n=10) or either of the low dose (25 mg/kg twice daily;
n=10) or two-tier (50 mg/kg for initial 17 days and then reduced to low dose; n=10) Cmpd-1 regimens from day 2 until the end point of the
experiment. A fourth group of mice (n=10) received weekly treatment of Zometa for 3 weeks beginning on day 3. The long bones were analyzed by
high resolution X-ray analysis and the degree of osteolytic damage was scored on a semi-quantitative scale, with a score of 0 representing no visible
damage and a score of 4 representing severe damage. The percentage of mice without (A) initial osteolytic damage (Cmpd-1 low p=0.027, two-tier
p=0.0037) or (B) substantial osteolytic damage (Cmpd-1 low p=NS, two-tier dose p=0.017) of the proximal tibia was significantly lower when
treated with Cmpd-1 compared to vehicle-treated mice (Kaplan-Meier analysis). (C) Examples of osteolytic lesions (shown using black arrowheads) in
long bones following the treatment with vehicle alone, Zometa or Cmpd-1 given under either the low dose or two-tier regimens are illustrated in the
panel and the lesion score is displayed on respective image.
doi:10.1371/journal.pone.0029615.g003
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Mammary fat pad growth of 4T1.2 mouse mammary tumor
cells was markedly inhibited in mice receiving either the low or the
high Cmpd-1 regimen (p,0.0003) compared to the vehicle group.
The high dose regimen was more effective from earlier time points
(day 16, 19 and 21, p#0.05, ,0.001 and ,0.001, respectively;
Bonferroni post-test) than the low dose regimen (only at day 21
p,0.05; Bonferroni post-test). Differences in tumor size between
vehicle control and treatment groups were not significant before
14 days post inoculation (Figure 4).
Cmpd-1 does not affect metastatic burden in soft tissues
In order to assess whether the metastatic burden in soft tissues
was affected by treatment with Cmpd-1, quantitative PCR for the
human Alu repeat sequence was performed on genomic DNA
isolated from the brains and lungs of the mice inoculated
intracardially with MDA-MB-231 cells. The results are presented
as the percentage of human DNA within each organ (Figure 5A–
B). No effect on metastatic tumor burden was observed with either
Cmpd-1 or Zometa, in line with the observation that overall
survival, represented by time of sacrifice, was not impacted upon
by treatment (Figure 5C).
The spontaneous metastases to the lung from mammary fat pad
4T1.2 tumors was assessed at the termination of the experiment
using ex-vivo IVIS imaging. As shown in Figure 5D, although the
high dose regimen showed a trend towards reduced lung
metastases, no significant difference was observed in the degree
of lung metastasis in animals receiving low or high Cmpd-1 and
the vehicle controls. Histological analysis of the lungs from the
mice inoculated with 4T1.2-Luc in mammary fat pad (n=4 per
group) revealed extensive lung metastases in each of the treatment
groups (Fig. 5E). Although the lung metastases in the high dose
Cmpd-1 treatment group appeared to be smaller, there was no
significant difference among the groups based on the metastatic
lesion counts from five randomly chosen fields. This is in
agreement with the luciferase intensity measured in these lungs
(Fig. 5D). The lungs from MDA-MB-231 experiments were
sacrificed for Alu analysis, and could not be subjected to this
analysis.
Effect of Cmpd-1 treatment on established tumor growth
in the xenograft model: An intervention study
An intervention study was undertaken with the high dose
regimen to test whether the Cmpd-1 was able to inhibit the growth
of established MDA-MB-231 xenografts. At day 27, when the
average tumor size was ,120 mm
3, mice were randomized into
two groups receiving either Cmpd-1 or vehicle twice daily at
,12 h intervals by oral gavage until harvest. At day 35, no
significant difference in tumor size was observed between the two
groups, thereby demonstrating successful randomization of mice
(Figure 6). Cmpd-1 was effective on established tumor growth
inhibition at the harvest time point (day 43) (p,0.01), but did not
achieve significance over the entire treatment period by RM-
ANOVA.
Serum concentrations of Cmpd-1 are well maintained,
and creatine kinase is not elevated
Blood was collected from a number of the intra-cardiac
inoculated mice at sacrifice and the serum concentration of
Cmpd-1 measured to determine whether it was concordant with
previous pharmacokinetic data (Pfizer, unpublished). For the
samples assessed, the serum concentration of Cmpd-1 was in the
range of 5–36 mg/ml (Figure 7). Although the mice were sacrificed
at different time points following their final dose of Cmpd-1 (5 to
6 hours or 11 to 12 hours), the distribution of Cmpd-1 serum
levels was similar.
The serum levels of creatine kinase from the 4T1.2 experiment
showed no significant differences (p=0.1339; one-way ANOVA)
when compared the vehicle control group (n=7, 280.76127.7)
with low Cmpd-1 (n=7, 537.26222.1) or high Cmpd-1 (n=5,
210.06140.6) (data not shown).
MMP13 is present in the intratumoral and extracellular/
tumor-stromal regions and vascular endothelial cells of
clinical primary breast cancer and experimental mice
tumors, and in osteoblasts in the breast to bone
metastases
Since we observed inhibition of primary tumor growth and
osteolytic lesions with Cmpd-1 treatment in mouse models, we
further examined MMP13 localization in clinical samples.
Primary human breast IDC samples (n=8) and breast-to-bone
metastases (n=5) were stained by immunofluorescence. The
proportion of cancer cells expressing MMP13 varied greatly,
ranging from no detectable MMP13 in 25% of patient samples,
through focal expression, to expression throughout most of the
tumor. Focal expression of MMP13 was also detected within
tumor-associated stroma or extracellular matrix in 75% of patient
samples, and all patient samples showed strong MMP13
immunoreactivity in the vasculature. The immunoreactivity of
MMP13 in primary tumors is summarised in Table 1, and
examples of MMP13 for two representative patients are shown in
Figure 8A. The immunolocalisation of MMP13 has also been
confirmed in the experimental mice tumors from xenograft and
syngeneic models using the above validated method. As depicted
in Figure 8B, in each case intratumoral staining, more abundant
stromal/extracellular staining, and prominent vascular staining
was observed.
The human bone metastases samples revealed positive MMP13
[33] staining by the tumor cells and osteoblasts cells while
Figure 4. Prevention treatment with Cmpd-1 and its effect on
primary tumor growth in a syngeneic mouse model of breast
cancer. Three groups of mice were inoculated with 4T1.2 cells into
mammary fat pad at day 0 and were treated with vehicle (n=8) or
either of the low (25 mg/kg twice daily; n=8) or high (50 mg/kg; n=8)
Cmpd-1 regimens from day 2 until the end point of the experiment. The
primary tumor growth was significantly delayed in mice treated with
low or high dose of Cmpd-1 compared with vehicle-treated mice
(p=0.0216 and p,0.0001, respectively; RM-ANOVA with Bonferroni
post-test). Each time point represents tumor measurements as mean 6
S.E.M.
doi:10.1371/journal.pone.0029615.g004
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largely negative (Figure 8C).
Proliferation remained unchanged in Cmpd-1 treated vs
untreated mice tumors
To examine the effect of Cmpd-1 on tumor cell proliferation,
we assessed the experimental mice tumors from each treatment
groups using Ki67 immunohistochemistry. As shown in represen-
tative images (Fig. 9), we observed abundant Ki67 positive nuclear
staining across all tumors from each treatment groups, with no
marked difference in the proliferation index.
Discussion
Cmpd-1 is an MMP13-selective inhibitor chosen from a panel
of pyrimidinetrione based molecules [27]. Its selectivity is high for
MMP13 (IC50 of 0.57 nM MMP13, 950 nM MMP1, 370 nM
Figure 5. Metastatic burden in the lungs (A) and brain (B) of mice treated with vehicle or Cmpd-1 (low or two-tier regimens)
following intra-cardiac inoculation of MDA-MB-231 cells, as assessed by qPCR for the human Alu repeat sequence on DNA
extracted from whole organs. Mouse only controls were included in the qPCR analysis and all mouse only samples were negative for human DNA.
Mean values are indicated. (C) Percentage survival of intra-cardially inoculated mice. Cmpd-1 did not prolong overall survival of the mice treated with
Cmpd-1 (Kaplan-Meier survival). (D) Metastatic burden in the lungs of mice treated with vehicle or Cmpd-1 (low or two-tier regimens) following
mammary fat pad inoculation of spontaneously metastasizing 4T1.2 cells. Tumor burden in lungs was assessed by luminescence intensity of ex-vivo
lung imaging using IVIS at the termination of the experiment. Cmpd-1 showed no inhibitory effect on metastatic tumor burden on soft tissues in
both xenograft and syngeneic mice models (Mann-Whitney test). (E) Representative images of lung macrometastasis in mice inoculated with 4T1.2-
Luc and treated placebo/low dose/high dose.
doi:10.1371/journal.pone.0029615.g005
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550 nM MMP12) [27]. It is anticipated that such MMP-selective
or -specific inhibitors will provide better therapeutic outcomes,
overcoming some of the problems encountered with previous
broad-spectrum inhibitors. Whilst broad-spectrum MMP inhibi-
tors were impressive in animal studies, many of these drugs did not
prove effective in the clinical setting, where a number of trials
showed toxicity such as MSS and also a lack of efficacy [37,38].
MSS seems not attributable to MMP13, as an orally available
MMP13 specific inhibitor developed through structure-based drug
design did not induce MSS symptoms in a rat model when used to
treat cartilage damage [39]. In the present study, serum levels of
creatine kinase, which is a general measure of muscle toxicity,
remained unchanged in mice treated with either low or high dose
of Cmpd-1 when compared with untreated group.
Our studies appear to have achieved pharmacologically relevant
dosing throughout the duration of Cmpd-1 administration. Eleven
to 12 hours after final drug administration the serum levels of
Cmpd-1 ranged from 5 to 36 mg/ml and were similar in samples
taken 5 to 6 hours after final dosage. These findings are in line
with previous pharmacokinetic profiling, where a maximal plasma
concentration of 16 mg/ml was obtained 4 hours after a single oral
administration of Cmpd-1 (25 mg/kg), dropping to 4 mg/ml by
24 hours (unpublished data). As calculated from the unbound
fraction of Cmpd-1 in mouse plasma (0.62%; unpublished data),
the lowest serum concentration of unbound Cmpd-1 observed in
our study equates to approximately 110-fold and 20-fold the
MMP13 IC50 for human (0.57 nM) [27] and rat (3.2 nM;
unpublished data) respectively. The rat MMP13 IC50 is likely to
be a reasonable estimate of the mouse MMP13 IC50, as the
sequence of the secondary structure elements of the rat and mouse
MMP13 active sites are identical [40].
We have shown that treatment with the MMP13-selective
inhibitor Cmpd-1 reduced the growth rate of two different
primary breast cancer models: The MDA-MB-231 human breast
cancer xenograft and the 4T1.2 syngeneic mouse model. Cmpd-1
was effective as a preventative agent in both models, and as an
interventional agent in the MDA-MB-231 xenograft model,
although the intervention effect was only apparent at largest
tumor sizes. Previously, broad-spectrum MMP inhibitors have
shown little benefit against pre-established preclinical models [41]
(also our unpublished data with AG3340 in the MDA-MB-231
model), so this effect is particularly important in light of the low
efficacy in previous clinical trials. During the latter stages of the
experiment the two-tier Cmpd-1 regimen in xenograft mice
exhibited a larger reduction in primary tumor growth rate than
the low Cmpd-1 regimen mice, despite both treatment groups
receiving the same low dose Cmpd-1 regimen from day 10
onwards. Similarly, a dose-dependent effect of Cmpd-1 was
observed on primary tumor growth in the syngeneic model of
mammary cancer. The latency period of these tumors did not
differ with treatment. Further, tumor cell proliferation with and
without Cmpd-1 treatment was evaluated. No obvious difference
in Ki67 positive staining was demonstrated among the groups
from xenograft and syngeneic models. These observations suggest
that the Cmpd-1-associated reduction in the primary tumor
growth rate may involve number of different factors that may or
may not relate to remodeling of the extracellular, and/or
vascularisation factors, and is the subject of further investigation.
Recently, Overall and coworkers identified a number of novel
MMP13 cleavage substrates that may be involved, including
inactivation of the chemokine CCL2, activation of platelet derived
growth factor-C and cleavage of SAA3, osteoprotegrin, Cut A and
antithrombin III [18].We speculate that early treatment of Cmpd-
1 may have reduced angiogenic seeding in the initial primary
tumor mass, but further analysis is required.
Primary tumors showed immunoreactivity of MMP13 in the
tumor cells and surrounding stroma/extracellular matrix. Previ-
ously we have shown that MMP13, while barely detectable in
naı ¨ve mammary fat pads, was abundantly expressed in the tumor-
associated murine stroma of breast cancer cell line and primary
tumor xenografts [11]. Such MMP13 localisation in the xenografts
was confirmed and extended to the mouse syngeneic model in the
present study. A study of 263 cases of invasive breast cancer
revealed MMP13 expression by both tumor cells and adjacent
fibroblasts, with high levels of MMP13 in these two cell types
strongly correlated with each other [5]. MMP13 immunoreactivity
in the cytoplasm of tumor cells has also been identified in 91% of
249 colorectal cancers resections [8]. A previous in situ
hybridisation study in ductal carcinoma in situ (DCIS) lesions
reported only stromal MMP13 mRNA expression and identified
the MMP13 positive cells as being myofibroblasts. Expression of
MMP13 was correlated with microinvasion events, leading the
authors to postulate that MMP13 may play a role in the transition
of DCIS to IDC [42]. Prominent MMP13 staining in the tumor
vasculature of IDC and in the mouse tumors of the present study
warrants further assessment. Recent studies support involvement
of MMP13 in tumor angiogenesis during melanoma progression
[10] and skin carcinoma [43].
Another important observation of this study was that Cmpd-1
treatment delayed the onset and reduced the severity of tumor-
induced osteolytic lesions in the experimental xenograft model of
bone metastasis following intra-cardiac inoculation of breast
cancer cells. A reduction in the incidence of substantial bone
lesions was observed for the two-tier Cmpd-1 regimen group, but
not the low dose regimen mice, despite both groups receiving the
same dosage from day 17 onwards. This change to lower dose was
prior to the first appearance of osteolytic damage. The anti-
osteolytic effects of Cmpd-1 treatment may result from reduced
tumor growth in the bone environment, similar to the reduced
primary tumor growth rate, and/or from direct inhibition of
osteolytic pathways. The present findings are further supported by
Nannuru et al, who found that treatment with MMP13 antisense
oligonucleotides reduces mammary tumor-induced osteolysis at
the tumor-bone interface, where they also found elevated MMP13
[17]. Furthermore, it has been shown that mice lacking MMP13
Figure 6. Intervention treatment with Cmpd-1. Mice were
inoculated with MDA-MB-231 cells at day 0 and randomized to receive
either vehicle (n=7) or high Cmpd-1 regimen (50 mg/kg; n=8) from
day 27 continued until harvest (day 43). Each time point of tumor
measurements plotted on the graph represents the mean 6 S.E.M.
Cmpd-1 inhibits established tumors in high dose treated mice at the
largest tumor size (p,0.01 by student-t test, p=NS by RM-ANOVA).
doi:10.1371/journal.pone.0029615.g006
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[12,24,44], and this is much more prominent in mice lacking both
MMP9 and MMP13 [13]. Thus, MMP13 inhibition may affect
both the growth and osteolytic consequences of breast carcinoma
cells metastasized to bone. These inhibitory effects of Cmpd-1
(MMP13-selective inhibitor) are consistent with the effects of
several broader-spectrum MMP inhibitors on osteolysis associated
with breast and prostate carcinoma cells [45]. These observations
suggest that MMP13-selective inhibition may be an important
mediator of preventing breast cancer induced bone osteolysis given
its regulatory role in bone remodelling. Although the Cmpd-1 (and
Zometa) delayed the development of osteolytic lesions in our
models, it did not improve the overall survival of mice in the
intracardiac model, such that the potential clinical utility against
metastatic breast cancer seems unlikely, however combination
therapy with both MMP13 inhibitors and bisphosphonates, or
other systemic therapies, remains to be tested.
Indeed, we detected MMP13 expression in the tumor and
osteoblasts cells in the bone metastases samples, whereas
osteoclasts were largely negative for MMP13. This is in agreement
with the literature reporting osteoblastic or periosteoclastic origins
of MMP13 expression in mice, and its’ involvement in bone
collagenolysis during tumor-induced osteolysis [46,47]. It is also
consistent with the dramatic induction of MMP13 expression in
cultured osteoblasts treated with the parathyroid hormone (PTH),
a bone resorption-inducing agent [48,49]. Immunolocalisation
studies revealed mononucleated cells in the resorption zones that
are present in close proximity of osteoclasts as a source of MMP13,
and suggest its involvement in the bone resorption and matrix
degradation [50,51]. In contrast, none of the MMPs expressed by
osteoclasts were found to limit the bone resorption via the direct
degradation of the bone matrix [52,53]. These findings strongly
suggest that MMP13 can be selectively expressed by primary
tumor and during cancer-induced osteolysis in bone metastasis.
As a comparator for any anti-osteolytic effects of Cmpd-1 we
used the bisphosphonate Zometa, which is known to block
osteolytic damage by inhibiting osteoclast-mediated bone resorp-
tion and also has demonstrated anti-tumor activity in preclinical
models (reviewed in [54]). In contrast to Cmpd-1, mice treated
with Zometa following intra-cardiac inoculation of MDA-MB-231
cells had complete abrogation of tumor-induced bone resorption,
but showed no increase in overall survival. Our results contrast
with data showing that Zometa, while reducing osteolytic damage
in bone, has the potential to increase tumor burden in soft tissues
[55]. Again, this may be a limitation of our particular isolate of
MDA-MB-231 cells, which appear biased to bone metastasis, and
rarely develop macroscopically visible metastases in soft tissues. It
will be important, in follow-up experiments, to determine whether
combination with MMP13 inhibitors will allow lower doses of
Zometa to be used, since the consequences of extended Zometa
use are not yet fully known, and some evidence of complications
such as osteonecrosis of the jaw have been observed [56].
Although the benefit was apparent in both primary tumor growth
and cancer cell induced osteolysis, suggesting that it is due to a
process common to both scenarios, there was no evidence of
reduced metastasis to either the lungs or brain of Cmpd-1 treated
mice. This differential response to Cmpd-1 may relate to the
involvement of tumor microenvironment at the orthotopic and
metastatic site. Similar to Cmpd-1, there was no evidence of
reduced metastasis to either the lungs or the brain of Zometa-
treated mice.
Collectively, our data suggest that MMP13-selective inhibitor
Cmpd-1 significantly reduces breast cancer burden at both the
Figure 7. Concentration of Cmpd-1 in serum collected at the
time of culling plotted against the time since last dose of
Cmpd-1.
doi:10.1371/journal.pone.0029615.g007
Table 1. Clinicopathologic details of breast cancer patients.
Patient #
Lymph node
Metastasis
Histological
Grade (1–3)
Estrogen receptor
Status
Progesteron
receptor Status
MMP13
Expression
1 Yes 2 +++ +++ T,S,V
2N o 1 +++ 2 T,S,V
3 N/A 1 +++ +++ T,V
4N o 1 +++ +++ T,V
5N o 2 ++ ++ T,S,V
6 N/A 2 +++ +++ S,V
7 Yes 2 +++ +++ T,S,V
8 Yes 2 +++ 2 S,V
Summary of MMP13 expression and clinicopathologic characteristics of primary breast tumors.
Tissue samples were graded and MMP13 expression was determined by immunofluorescence, as described in Materials and Methods. All patients were diagnosed with
invasive/infiltrating ductal carcinoma (IDC). The MMP13 immunofluorescence images of the samples from Patients 1 and 2 are shown in Figure 7. N/A=not available.
The tumors from all the patients, except patient 7 where HER-2 status was not determined, were negative for HER-2. Estrogen receptor and progesterone receptor
status was graded as 2=negative, +=weak, ++=intermediate and +++=strong expression. MMP13 expression was determined as intra-tumor (T), stromal (S) and
vasculature (V).
doi:10.1371/journal.pone.0029615.t001
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Immunofluorescence staining was performed on FFPE sections for MMP13 using a sheep polyclonal MMP-13 antibody as indicated by green
fluorescence, whereas nuclei are stained red with propidium iodide. Parallel sections from the same tissue blocks were probed with control sheep
serum to monitor for non-immune background (lack of green signal displayed as an inset in each panel). (B) Representative images of MMP13
immunofluorescence (green) from the syngeneic (top panel) and xenograft (bottom panel) mouse tumors. (C) MMP13 immunofluorescence (red) in
human breast to bone metastasis. Dashed box in upper panels represents area of magnification in lower panels. Multinucleated (DAPI; blue)
osteoclasts (TRAcP; green) were identified at the tumor-bone interface (represented by dashed line in the lower panels).
doi:10.1371/journal.pone.0029615.g008
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severity of tumor-induced bone osteolysis was also reduced.
Together, these results indicate critical involvement of MMP13
in clinical breast carcinoma. MMP13 inhibition lacks MSS-like
side effects, which was a major limitation in earlier trials of less
specific MMP inhibitors. Combined with the lack of any apparent
adverse tumor promotion due to MMP13 deficiency in MMP13-
null mice, MMP13 may represent a new therapeutic target in
breast cancer.
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